Karachalios G N, Houpas P, Tziviskou E, Papalimneou V, Georgiou A, Karachaliou I, Halkiadaki D
3rd Department of Medicine, Red Cross Hospital, Athens, Greece.
Int J Clin Pharmacol Ther. 1998 Oct;36(10):561-4.
The efficacy and safety of amikacin administered once-daily versus twice-daily was evaluated in adult patients with systemic infections. Patients over 23 years of age with suspected or documented systemic infections were randomly divided into two groups: one group received amikacin intravenously 15 mg/kg once-daily, and the other group received amikacin 15 mg/kg divided into 2 doses. The efficacy of both dosage regimens was very good with a satisfactory clinical response in 90.2% and 89%, respectively. The bacteriological cure rate was 82.2% and 76%, respectively. There were no significant differences between the 2 regimens as far as what efficacy and safety are concerned. Nephrotoxicity appeared in 2 patients of the first group and 3 patients of the second, but did not lead to discontinuation of amikacin. No significant differences between the regimens with regard to hearing loss or prodromal signs of ototoxicity. We concluded that amikacin administered once-daily appears to be as effective and safe as the twice-daily dosing. However, the once-daily administration is more convenient and less costly.
在患有全身感染的成年患者中，评估了阿米卡星每日一次给药与每日两次给药的疗效和安全性。年龄超过23岁、疑似或确诊为全身感染的患者被随机分为两组：一组静脉注射阿米卡星15mg/kg，每日一次；另一组接受阿米卡星15mg/kg，分2剂给药。两种给药方案的疗效都非常好，临床有效率分别为90.2%和89%。细菌学治愈率分别为82.2%和76%。就疗效和安全性而言，两种方案之间没有显著差异。第一组有2例患者出现肾毒性，第二组有3例患者出现肾毒性，但均未导致停用阿米卡星。在听力损失或耳毒性前驱症状方面，两种方案之间没有显著差异。我们得出结论，每日一次给药的阿米卡星似乎与每日两次给药一样有效和安全。然而，每日一次给药更方便且成本更低。
